FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

LYKALABS

20.1
+0 (0%)
Updated 03:49 01/07 IST

LYKALABS Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for LYKALABS
Disclaimer
0% Bullish
0% Bearish

LYKALABS Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See LYKALABS Share Price Targets >>

LYKALABS Ratings

Long term LYKALABS rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live LYKALABS message board: Is LYKALABS buy or sell? Should I buy LYKALABS shares? Why are LYKALABS shares falling? Should I invest in LYKALABS stock?

  1. Home
  2. LYKALABS Forum

LYKALABS Share Price Discussion

N
Reputation: 3,627 • Jun 24 4:56 AM
Share market update: 75 stocks hit 52-week highs on NSE
Overall, 17 shares were trading in green in Nifty50 index, while 33 were trading in red.
The Economic Times
Like
Reply
N
Reputation: 3,627 • Jun 12 3:28 AM
Lyka Labs Consolidated March 2020 Net Sales at Rs 15.07 crore, down 36.91% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,627 • Jun 12 3:28 AM
Lyka Labs Standalone March 2020 Net Sales at Rs 8.57 crore, down 41.84% Y-o-Y
Moneycontrol
Like
Reply
N
Reputation: 3,627 • Jun 5 6:16 AM
COVID-19 restrictions affected sales, created liquidity crunch: Lyka Labs
Lyka Labs further said "parties who have placed orders with the company have deferred the execution of orders, as a result, sales has been affected and created liquidity crunch."
The Economic Times
Like
Reply
N
Reputation: 3,627 • Jun 5 5:23 AM
COVID-19 restrictions affected sales, created liquidity crunch: Lyka Labs
"There has been interruption in supply of raw material and packing material to the factory," it added.
Moneycontrol
Like
Reply
N
Reputation: 3,627 • Aug 12, 2019 8:33 AM
Lyka Labs Consolidated June 2019 Net Sales at Rs 14.36 crore, up 0% Y-o-Y
www.moneycontrol.com
Like
Reply
N
Reputation: 3,627 • Aug 12, 2019 8:33 AM
Lyka Labs Standalone June 2019 Net Sales at Rs 6.74 crore, down 40.61% Y-o-Y
moneycontrol.com
Like
Reply
N
Reputation: 3,627 • May 20, 2019 8:18 AM
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • LYKALABS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization68.94
    Enterprise Value160.06
    Price to Earnings210.23
    Price to Book Value0.7
    Return on Capital Employed-0.02
    Return on Equity-0.11
    Face Value10
    Dividend YieldNA
  • LYKALABS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 120.9520.9519.5520.1
    Jun 302122.252020.2
    Jun 2922.522.72121.35
    Jun 2624.424.721.7522.15
    Jun 2521.3523.452023.35
  • LYKALABS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹19.27
    30 Day Moving Average₹18.16
    50 Day Moving Average₹17.52
    100 Day Moving Average₹17.16
    200 Day Moving Average₹17.54
  • LYKALABS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue41.6878.59-0.47
    Operating Profit-0.5118.28-1.03
    Profit Before Tax-11.220.57-20.68
    Net Income-10.840.57-20.02
  • LYKALABS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds98.696.030.03
    Total Liabilities150.1149.550
    Total Assets248.7245.580.01
  • LYKALABS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity6.911.21-0.38
    Cash from Investing Activity-3.35-5.19-0.35
    Cash from Financing Activity-4.48-6.3-0.29
    Net Cash Flow-0.93-0.282.32
  • LYKALABS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.04NA
    Return on Equity-0.110.01
    Return on Capital Employed-0.020.09
  • LYKALABS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.08
    3 Year CAGR Growth in Operating Profit1.98
    3 Year CAGR Growth in EBIDTA-0.09
    3 Year CAGR Growth in Net Income1.08
    3 Yr CAGR Growth - Diluted EPS1.08
  • LYKALABS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.44
    5 Year CAGR Growth in Operating Profit1.25
    5 Year CAGR Growth in EBIDTA-0.1
    5 Year CAGR Growth in Net Income1.1
    3 Yr CAGR Growth - Diluted EPS1.1
  • LYKALABS - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 12 3:28 AM
    Lyka Labs Consolidated March 2020 Net Sales at Rs 15.07 crore, down 36.91% Y-o-Y
    Moneycontrol
    NewsBot
    Jun 12 3:28 AM
    Lyka Labs Standalone March 2020 Net Sales at Rs 8.57 crore, down 41.84% Y-o-Y
    Moneycontrol
    NewsBot
    Jun 5 6:16 AM
    COVID-19 restrictions affected sales, created liquidity crunch: Lyka Labs
    The Economic Times
    NewsBot
    Jun 5 5:23 AM
    COVID-19 restrictions affected sales, created liquidity crunch: Lyka Labs
    Moneycontrol
    NewsBot
    Aug 12, 2019 8:33 AM
    Lyka Labs Consolidated June 2019 Net Sales at Rs 14.36 crore, up 0% Y-o-Y
    www.moneycontrol.com
    NewsBot
    Aug 12, 2019 8:33 AM
    Lyka Labs Standalone June 2019 Net Sales at Rs 6.74 crore, down 40.61% Y-o-Y
    moneycontrol.com
    NewsBot
    May 20, 2019 8:18 AM
    NewsBot
    Mar 31, 2019 12:38 PM
    NewsBot
    Feb 13, 2019 5:27 AM
    NewsBot
    Jan 11, 2019 2:02 AM
  • LYKALABS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020